CCNQ pseudogene 2 (CCNQP2)

CCNQ pseudogene 2 (also referred to as FAM58Y) is classified as a pseudogene in the human genome. Pseudogenes do not encode functional proteins and generally arise from duplication or retrotransposition events of protein-coding genes, followed by accumulation of disabling mutations. Some pseudogenes, in rare cases, may have roles as non-coding RNA molecules that regulate gene expression, for example as competing endogenous RNAs; however, there is currently no evidence that CCNQ pseudogene 2 (CCNQP2) is biologically functional or involved in any signaling, disease, or drug response pathway. The functional CCNQ gene (not the pseudogene) encodes a cyclin which has established roles in cell cycles and has been associated with developmental disorders[1]. In contrast, CCNQP2 is not recognized as a protein-coding gene, receptor, or validated therapeutic target. Additional Notes: - **is_incorrect:** The inclusion of CCNQP2 as a therapeutic target is likely incorrect; it is not a receptor or any pharmacologically interest-bearing molecule. In research, pseudogenes may be studied for possible regulatory RNA functions (as discussed broadly for pseudogenes), but these are highly context-specific and unproven for CCNQP2[2][3]. - **Related gene:** The protein-coding gene "CCNQ" (Cyclin Q), also known by the previous symbol FAM58A, is genetically distinct from FAM58Y/CCNQP2. CCNQ mutations are causative for STAR syndrome, but again, this does not pertain to the pseudogene[1]. If you intended a *protein-coding* receptor or enzyme, or the gene encoding cyclin Q, the relevant target is "Cyclin Q (CCNQ or FAM58A)"[1]. The symbol FAM58Y refers to a pseudogene (Y chromosome paralog), and should not be used as a drug target entry. Pseudogenes in general may have RNA-level regulatory effects, but these are not established for CCNQP2, making it inappropriate as a current drug discovery target or biomarker[2][3].

Other names

FAM58Y